AZD7503

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Healthy ParticipantsPharmacokineticsSafetySteatohepatitisTolerability

Phase 1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

CompletedNCT05143905

AstraZenecaHealthy Participants, Pharmacokinetics, Safety +1

Start: 2021-12-06End: 2022-11-09Updated: 2025-02-19

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

TerminatedNCT05864391

AstraZenecaSteatohepatitis

Start: 2023-03-31End: 2024-03-20Updated: 2025-07-20